title: Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients.
abstract: In a series of 218 subjects diagnosed as having nonleukemic chronic myeloproliferative disorders in a single institution within a 18-year period, 13 instances of acute transformation were registered. They corresponded to 8 out of 70 patients with idiopathic myelofibrosis (IM), 4 out of 91 with polycythemia vera (PV), and 1 out of 57 with essential thrombocythemia (ET). The actuarial probability of developing such a complication at 100 months from diagnosis reached 20.6% in IM, 8.7% in PV, and 4% in ET. Only 1 IM patient whose condition developed into acute leukemia had received prior cytolytic therapy, whereas, in contrast, all PV and ET patients showing this pattern had previously been treated with either 32P or alkylating agents. On the other hand, acute transformation in IM generally had an insidious presentation, contrasting with its abrupt onset in most PV and ET patients. Most acute leukemias (12 out of 13) exhibited a myeloid phenotype. The patients' median survival from diagnosis of the acute transformation was only 3 months, the development of this complication significantly shortening the patients' overall survival.
authors.affiliation: Postgraduate School of Hematology Farreras Valentí, Hospital Clínico, University of Barcelona, Spain.
authors.forename: F
authors.initials: F
authors.lastname: Cervantes
authors.forename: D
authors.initials: D
authors.lastname: Tassies
authors.forename: C
authors.initials: C
authors.lastname: Salgado
authors.forename: M
authors.initials: M
authors.lastname: Rovira
authors.forename: A
authors.initials: A
authors.lastname: Pereira
authors.forename: C
authors.initials: C
authors.lastname: Rozman
mesh_terms: D000206:Actuarial Analysis; D000208:Acute Disease; D002908:Chronic Disease; D003131:Combined Modality Therapy; D006801:Humans; D009196:Myeloproliferative Disorders / Q000150:complications* / Q000453:epidemiology / Q000401:mortality; D011087:Polycythemia Vera / Q000453:epidemiology / Q000209:etiology / Q000401:mortality / Q000628:therapy; D055728:Primary Myelofibrosis / Q000453:epidemiology / Q000209:etiology / Q000401:mortality / Q000628:therapy; D011336:Probability; D013030:Spain / Q000453:epidemiology; D016019:Survival Analysis; D013920:Thrombocythemia, Essential / Q000453:epidemiology / Q000209:etiology / Q000401:mortality / Q000628:therapy